<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622581</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-TRK-0315</org_study_id>
    <nct_id>NCT02622581</nct_id>
  </id_info>
  <brief_title>Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients</brief_title>
  <acronym>CRISP</acronym>
  <official_title>Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, non-interventional, prospective, multi-center clinical research platform with the main
      objective to assess molecular biomarker testing, treatment and outcome of patients with
      advanced or metastatic NSCLC in Germany
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and
      outcome of unselected patients in real-life practice, is crucial to evaluate and improve the
      quality of care for patients with metastatic non-small cell lung cancer (NSCLC). The purpose
      of CRISP is to set up a national clinical research platform to document uniform data on the
      molecular testing, treatment, course of disease in patients with advanced or metastatic NSCLC
      not amenable to curative treatment. A particular focus is on molecular biomarker testing of
      patients before the start of first-line treatment. The data shall be used to assess the
      current state of care and to develop recommendations concerning topics that could be
      improved. PRO assessment will provide large-scale data on quality of life and
      anxiety/depression for real-life patients in routine practice. In addition, two
      questionnaires (concerning individual quality of life and patient-caregiver communication)
      will be validated in German patients with metastatic NSCLC. Furthermore CRISP will set up a
      decentralized clinically annotated tissue repository for future collaborative,
      investigational scientific biomarker testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>biomarker</measure>
    <time_frame>3 years</time_frame>
    <description>To collect data on the frequency, methodology and results of molecular biomarker testing before first-line and later-line treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>treatment</measure>
    <time_frame>3 years</time_frame>
    <description>To describe systemic treatments and sequential treatments applied in real-life practice</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
    <description>To assess effectiveness of systemic treatments in regards to response rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>3 years</time_frame>
    <description>To assess effectiveness of systemic treatments in regards to progression free survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>To assess effectiveness of systemic treatments in regards overall survival.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>physician-reported factors</measure>
    <time_frame>3 years</time_frame>
    <description>To describe physician-reported factors affecting treatment decision making besides biomarker profiling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>supportive therapies</measure>
    <time_frame>3 years</time_frame>
    <description>to collect key data on specific supportive therapies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes during the project</measure>
    <time_frame>3 years</time_frame>
    <description>To investigate changes in diagnostics, treatment or outcome during the course of the project</description>
  </primary_outcome>
  <primary_outcome>
    <measure>general health-related and individual quality of life (QoL) patient-reported outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate patient-reported outcomes concerning (1) general health-related and individual quality of life (QoL). and depression, (4) patient-caregiver communication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>physical and psychological well-being patient-reported outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate patient-reported outcomes concerning physical and psychological well-being.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>anxiety patient-reported outcomes</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate patient-reported outcomes concerning anxiety.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Metastatic Non-small Cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>Non-squamous cell carcinoma</arm_group_label>
    <description>3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Squamous cell carcinoma</arm_group_label>
    <description>1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-squamous cell carcinoma (not tested)</arm_group_label>
    <description>Not tested for molecular alterations (CRISP-Satellite).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.</description>
    <arm_group_label>Non-squamous cell carcinoma</arm_group_label>
    <arm_group_label>Squamous cell carcinoma</arm_group_label>
    <arm_group_label>Non-squamous cell carcinoma (not tested)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All patients will be asked to give consent for their tumor samples to be used for future
      investigational translational research. If the patient agrees, contact details of the local
      pathology where the tumor sample is stored as well as the sample's identification number will
      be documented in the eCRF, creating the CRISP &quot;decentralized clinically annotated tissue
      repository&quot;. Study sites will inform the local pathologists about the patient's consent and
      ask for the tissue sample to be reserved for future CRISP analyses.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with locally advanced or metastatic NSCLC at the start of palliative first-line
        systemic therapy. Of all patients recruited, 3,250 patients with nonsquamous cell carcinoma
        will be tested for molecular alterations at the start of first-line treatment (CRISP
        patients). 1,750 patients with squamous can be tested for molecular alterations at the
        start of first-line treatment (CRISP patients). The remainder will be patients with
        untested non-squamous carcinoma (CRISP satellite patients). Patients will be recruited in
        up to 150 study sites (certified lung cancer centers, comprehensive cancer centers,
        hospitals and office-based oncology practices) in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer (NSCLC)

          -  Stage IV or stage IIIB (UICC7) if patient is ineligible for curative surgery and/or
             radiochemotherapy

          -  Informed consent no later than four weeks after start of (palliative) firstline
             treatment

          -  Age â‰¥ 18 years

          -  Able to understand and willing to sign written Informed Consent and to complete
             patient-reported-outcome assessment instruments

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Griesinger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pius-Hospital Oldenburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aysun Karatas, Dr.</last_name>
    <email>aysun.karatas@aio-studien-ggmbh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Hipper, Dr.</last_name>
    <email>annette.hipper@aio-studien-ggmbh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pius-Hospital</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Griesinger, Prof.</last_name>
      <phone>+49 441 229 1611</phone>
      <email>Frank.griesinger@pius-hospital.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>AIO - Working Group for Medical Oncology from the German Cancer Society</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

